@article{3105804,
    title = "Vinflunine in the treatment of relapsed metastatic urothelial cancer: A systematic review and meta-analysis of real-world series",
    author = "Bamias, A. and Hegele, A. and Medioni, J. and Castellano, D. and Doni, L. and Passalacqua, R. and Zagouri, F. and Tzannis, K. and Hussain, S. and Ullen, A.",
    journal = "Critical Reviews in Oncology/Hematology",
    year = "2019",
    volume = "140",
    pages = "80-87",
    publisher = "Elsevier Ireland Ltd",
    issn = "1040-8428",
    doi = "10.1016/j.critrevonc.2019.05.006",
    keywords = "vinflunine;  antineoplastic agent;  platinum derivative;  vinblastine;  vinflunine, anemia;  asthenia;  cancer prognosis;  cancer recurrence;  constipation;  drug efficacy;  drug response;  drug safety;  drug utilization;  fatigue;  fever;  human;  meta analysis;  metastasis;  nausea and vomiting;  neutropenia;  overall survival;  progression free survival;  Review;  systematic review;  thrombocytopenia;  transitional cell carcinoma;  aged;  constipation;  Europe;  fatigue;  female;  male;  metastasis;  middle aged;  nausea;  pathology;  recurrent disease;  treatment outcome;  urinary tract tumor;  vomiting, Aged;  Antineoplastic Combined Chemotherapy Protocols;  Constipation;  Europe;  Fatigue;  Female;  Humans;  Male;  Middle Aged;  Nausea;  Neoplasm Metastasis;  Platinum Compounds;  Recurrence;  Treatment Outcome;  Urologic Neoplasms;  Vinblastine;  Vomiting",
    abstract = "Background: Vinflunine (VFL) is approved in Europe as second-line treatment of metastatic urothelial cancer after failure of platinum-containing therapy. We performed a systematic review and meta-analysis of real-world data (RWD) to assess utilization, efficacy and safety of VFL. Methods: We performed a MEDLINE search for the period of 1/1/2000-31/8/2017. Full-length articles providing post-marketing RWD on VFL in patients failing previous chemotherapy were eligible. Interventional clinical trials were excluded. Results: Ten studies with 797 patients were identified. According to pooled REs analysis, overall response rate was 19%, most frequent, all-grade toxicities were fatigue (41%), constipation (39%), nausea/vomiting (25%), and most prevalent Grade 3–4 toxicities were neutropenia (13%), anaemia (9%), fatigue (8%). Median OS was comparable to results reported in recent randomized studies. Conclusion: Our findings confirm the efficacy and safety of VFL in an unselected population and support the use of VFL in the changing treatment paradigm of relapsed mUC. © 2019 Elsevier B.V."
}